Sign in
FI

FIDUS INVESTMENT Corp (FDUS)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 delivered total investment income of $37.5M, NII of $18.6M ($0.55/share) and adjusted NII of $18.4M ($0.54/share), with NAV at $19.33/share; year-over-year adjusted NII per share declined due to lower yields and a higher share count .
  • Originations ($120.3M) and repayments ($122.8M) were balanced; debt portfolio first-lien mix rose to 76%, weighted average debt yield eased to 13.3%, and nonaccruals remained under 1% of fair value (4.1% of cost), highlighting healthy credit quality despite a write-down of Quantum IR Technologies to zero .
  • Board declared Q1 2025 dividends totaling $0.54/share (base $0.43 + supplemental $0.11), down from Q4’s $0.61/share; management reiterated target leverage of ~1.0x and expects yields to stay “pretty stable” near current levels .
  • Post-quarter catalysts: realized equity gains (~$3.2M Healthfuse, ~$8.2M Medsurant) and incremental SBA debentures issuance, supporting liquidity and capital deployment into 2025 .

What Went Well and What Went Wrong

  • What Went Well

    • Portfolio resiliency: “Our debt portfolio continues to perform well with sound credit quality… our equity portfolio… continues to deliver net realized gains” .
    • Healthy activity and composition: First-lien debt 76% of debt FV, variable-rate debt 74.5% of debt portfolio; originations of $120.3M across five new companies .
    • Dividend sustainability and spillover: Q4 paid $0.61/share; estimated spillover income of $45.6M ($1.34/share) at year-end supports ongoing supplemental dividends .

  • What Went Wrong

    • Earnings per share compression: Adjusted NII/share declined to $0.54 (vs $0.65 YoY) on lower yields (SOFR decline) and higher average shares outstanding from ATM issuances .
    • Yield pressure: Weighted average debt yield fell to 13.3% (from 13.8% in Q3), reflecting competitive spreads and rate resets .
    • Idiosyncratic credit event: Quantum IR Technologies added to nonaccruals and written down to zero, highlighting company-specific risk in last‑out first‑lien exposure .

Financial Results

MetricQ4 2023Q3 2024Q4 2024
Total Investment Income ($USD Millions)$36.3 $38.4 $37.5
Net Investment Income ($USD Millions)$16.9 $21.4 $18.6
NII per Share ($)$0.58 $0.64 $0.55
Adjusted NII per Share ($)$0.65 $0.61 $0.54
Net Increase in Net Assets from Operations per Share ($)$0.91 $0.49 $0.52
Dividends Declared per Share ($)$0.80 $0.57 $0.61
NAV per Share ($)$19.37 $19.42 $19.33

KPIs and Portfolio Composition

KPIQ2 2024Q3 2024Q4 2024
Originations ($USD Millions)$62.4 $65.9 $120.3
Repayments/Realizations ($USD Millions)$43.1 $50.8 $122.8
New Portfolio Companies (#)1 3 5
Portfolio FV ($USD Billions)$1.08 $1.09 $1.10
Debt Portfolio FV ($USD Millions)$945.7 $959.4 $944.5
Equity Portfolio FV ($USD Millions)$132.7 $131.3 $146.0
First-Lien Debt (% of Debt FV)71% 73% 76%
Variable-Rate Debt (% of Debt FV)72.8% 73.2% 74.5%
Weighted Avg Debt Yield (%)14.0% 13.8% 13.3%
Nonaccruals (% of FV / % of Cost)Under 1% FV Under 1% FV Under 1% FV / 4.1% cost
Net Debt-to-Equity (x)0.7x 0.7x 0.7x

Segment Highlights (New Investments in Q4)

CompanyInvestment TypeSize
Axis Medical Technologies (MoveMedical)First lien + preferred equity (+ commitment)$14.8M + $0.8M
CP CommunicationsFirst lien + subordinated + common equity$8.4M
Estex ManufacturingFirst lien + common equity$6.3M
FumexFirst lien + common equity$7.4M
World ToursFirst lien + preferred equity$7.0M

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Quarterly Dividends (Total per share)Q1 2025$0.61 (Q4 2024 actual paid: $0.43 base + $0.18 supplemental) $0.54 ($0.43 base + $0.11 supplemental) Lowered
Leverage Target (Net Debt/Equity)Ongoing~1.0x target (longstanding) ~1.0x target reiterated Maintained
ATM Equity Program UsageNear-termUsed earlier in 2024 “Did not use the ATM last quarter” and opportunistic going forward Maintained opportunistic stance
Yield Outlook2025N/A“Yields are probably here for a little while” (stable) Outlook: stable

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2/Q3)Current Period (Q4)Trend
Yields/SpreadsQ2: 14.0% yield, competitive spreads; Q3: 13.8% yield, spread compression amid competition Expect yields to stay “pretty stable” near current levels Stabilizing
Credit Quality & NonaccrualsQ2/Q3: Nonaccruals under 1% FV; sound credit quality Nonaccruals under 1% FV, 4.1% cost; Quantum IR added and written down to 0 Slightly negative (idiosyncratic)
M&A/Deal ActivityQ2: Reasonable deal flow; Q3: moderate, uptick expected Q4 Q4 active; originations ≈ repayments; post-quarter new investments Active but balanced
Balance Sheet LeverageQ2: Underlevered, flexible sources (revolver, SBIC) Target ~1.0x reiterated; ~0.7x current Stable
Tariffs/MacroQ3: pockets of softness in industrial/consumer Potential tariff cost impacts “not significant”; companies have pricing power Manageable
Equity MonetizationsQ2: $9.2M realized gains Q1 2025 distributions: ~$3.2M Healthfuse, ~$8.2M Medsurant Positive realizations

Management Commentary

  • Portfolio/strategy: “Our strategy is clearly working. Overall, our portfolio is healthy… our equity portfolio… continues to deliver net realized gains” (Ed Ross) .
  • Yield outlook: “Yields are probably here for a little while… there’s a fair bit of capital out there… interest in trying to keep portfolios… grow them” (Ed Ross) .
  • Leverage/tone: “We’re probably 1:1 leverage is the target… we did not use the ATM program [last quarter]” (Ed Ross) .
  • Macro/tariffs: “Costs going up… most of our portfolio companies have pricing power… we don’t expect any huge changes in portfolio performance” (Ed Ross) .
  • Portfolio cushion: Average leverage ~4.25x in core LMM; loan-to-value ~41% (≈60% equity cushion), interest coverage high (Ed Ross) .

Q&A Highlights

  • Yields/spreads: Management expects yields to remain stable; opportunities may exist where perceived risk is mispriced .
  • Quantum IR nonaccrual: Last‑out first‑lien position; active engagement; write-down reflects company-specific negative events (Ed/Shelby) .
  • Distributions accounting: Healthfuse/Medsurant distributions booked as return of capital and realized gains; Q4 fair values anticipated Q1 repayments (Shelby) .
  • Leverage strategy: Target ~1.0x; balanced approach using debt majority; opportunistic ATM usage (Ed) .
  • Macro exposure/tariffs: Limited impact expected; portfolio companies possess pricing power; modest EBITDA growth across debt portfolio companies (Ed) .

Estimates Context

  • Wall Street consensus EPS and revenue (S&P Global) were unavailable in this session due to a request limit error, so comparisons to estimates could not be made. Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Dividend path: Total Q1 2025 dividends of $0.54/share reflect lower supplemental payout vs Q4; sustainability supported by spillover income and healthy NII coverage .
  • Credit watch: Nonaccruals remain low, but Quantum IR write-down underscores idiosyncratic risk; diversified first-lien tilt and equity cushions mitigate downside .
  • Yield dynamics: Weighted average yield drifted to 13.3%; management sees stability ahead, limiting near-term NII upside absent mix/pricing changes .
  • Deployment capacity: Liquidity ~$175.7M at year-end; incremental SBA debentures and post-quarter originations support continued selective growth without overlevering .
  • Equity monetization: Realized gains (Healthfuse/Medsurant) enhance returns; continued episodic equity exits likely, a key medium-term alpha driver .
  • Trading lens: Near-term stock catalysts include dividend declarations, realized gains, and credit headlines; tone on yields/spreads and any new nonaccruals will be scrutinized .
  • Thesis: Lower-middle-market first-lien focus, pricing power at portfolio companies, and disciplined leverage (~0.7x current vs ~1.0x target) position FDUS to compound NAV and deliver attractive risk-adjusted distributions over the medium term .